|

Universal anti-CD70 CAR-T (CHT101) Clinical Trials

1 actively recruiting trial

Pipeline

Early 1: 1

Top Sponsors

  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School1

Indications

  • Systemic Lupus Erythematosus (SLE)1
  • Lupus1

Other1 trial

Universal Anti-CD70 CAR-T (CHT101) Cell Therapy for Relapsed Refractory Systemic Lupus Erythematosus
Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.